The 10th Annual VirtueInsight Pharma Pricing, Reimbursement & Market Access (PRMA) Conference brings together senior pharmaceutical leaders, market access professionals, payers, and policy experts to examine the forces reshaping access and pricing strategy across global healthcare markets. Across two days of keynote presentations, panel discussions, and collaborative workshops, the programme explores the policy changes, negotiation dynamics, and commercial challenges influencing market access today.
Verpora’s Head of Payers, Omar Ali, will play a prominent role throughout the conference, delivering the opening keynote, leading a collaborative roundtable on Innovative Contracting and Value-Based Agreements, and moderating a senior industry panel on evolving market access strategy. Drawing on insights from Verpora’s global payer network, Omar’s sessions will examine the changing realities of drug price negotiations, value-based agreements, and the strategic implications of new payer and regulatory approaches around the world.
KEYNOTE / DAY ONE Weds 2 September, 2026, 09:00 PM (ET)
Payer Access Diaries: Theatre of MFN Price Negotiations, CMS Drug Price Negotiations and the Rare Disease Reckoning
There is a seismic shift occurring in how the world’s governments and payers value.
Innovative medicines and pricing dynamics. The rules of engagement for drug price negotiations have been fundamentally rewritten—not just in Washington, D.C., but in every major market across the globe.
In this keynote, Omar Ali pulls back the curtain on the “Payer Access Diaries.” These are the unfiltered, behind-the-scenes accounts of global payer negotiations from the last 18 months. These case studies come directly from the source: anonymized perspectives from the payer network, narrating the specific strategies and renewed fervor they are bringing to the table when it comes to new drug launches, indication & lifecycle management and negotiation strategies that effect net price protection.
Keynote Themes
The CMS Watershed: A deep dive into the US drug price negotiation landscape, how CMS is negotiating and its ripple effects on global innovation
The Rare Disease Bubble: Analyzing the “Burst Phenomena” and why the industry’s safest haven is becoming its most volatile battleground.
Payer Negotiation Revelations: Examining the specific negotiation strategies deployed in the context of MFN and how “value” is being redefined in real-time.
“These payer accounts won’t just inform your strategy; they will change your perspective on the future of the industry & will stay with you long after the conference ends.”
COLLABORATIVE BREAKOUT SESSION / DAY ONE Weds 2 September, 2026, 4:00 PM (ET)
Innovative Contracting & Value-Based Agreements
6 distinct roundtable topics, each led by 2 table speakers, in a session designed for maximum cross-pollination of ideas.
In this session, Omar Ali and a second host discuss Innovative Contracting and Value Based Agreements - How are they negotiated, deployed & operationalised? How terms should be negotiated?
KEYNOTE PANEL DISCUSSION / DAY TWO Weds 2 September, 2026, 11:10 AM (ET)
Regulatory - New Rules, New Strategies: Winning under new rules: Market Access strategies for a shifting landscape
Moderated by Omar Ali, with panelists:
DINAKARAN BALASUBRAMANIAN, Dr. Reddy’s Laboratories
ROBERT KEMP, Breath Therapeutics
UMANG SHASTRI, Ferring Pharmaceuticals
Omar Ali
Head of Payers, Verpora
& Former Adviser to NICE
About Omar Ali
More Info & Registration
More information and registration directly via the VirtueInsight website…